FluidFM CRISPR gene editing

Webinar & Demo | by Olympus

Registrations are closed
Odoo • Text and Image

Webinar organized by 

Olympus Life Science and Cytosurge have teamed up to present a webinar on how to overcome one of the biggest challenges in gene editing: delivery of reagents into the nucleus.

With traditional delivery methods, such as lipofection or electroporation, the success of CRISPR-Cas mediated gene editing is limited and stressful for the cells. Typically, only one edit can be introduced at once, and its size will be limited. The reagents must pass through the cell membrane, cytoplasm, and nuclear envelope before reaching the nucleus. Traditional delivery methods are not optimized for this long journey, which explains why low transfection efficiency rates are common and often coupled with low viability.

The Cytosurge FluidFM BOT BIO Series can overcome the limitations of traditional transfection methods by directly delivering the desired cargo with a force-sensitive nanosyringe into the nucleus. This method is easy, cargo-independent, and gentle, enabling you to introduce well-defined mixes, such as Cas9, repair templates, and multiple gRNA into the cell nucleus.

Improved efficiency and viability are especially critical when working with rare or hard-to-transfect cells such as induced pluripotent stem cells (iPSCs), neurons, or cardiomyocytes—or when delivering large repair templates.

See these improvements for yourself by registering today. You’ll learn:

  • How the FluidFM BOT BIO Series overcomes established gene editing limitations

  • How the nano-injection process works through a live demonstration

Presented by:
Dr. Paul Monnier, Life Science Application Scientist
Dr. Pablo Doerig, VP Research Solutions

Two sessions:
September 30, 2020 at 10am EDT, 4pm CEST
September 30, 2020 at 2pm EDT, 8pm CEST

Register now

Date & Time
Wednesday September 30, 2020
4:00 PM 5:00 PM (Europe/Zurich)

Olympus America Inc.

--Olympus America Inc.--

Find out what people see and say about this event, and join the conversation.